Montpellier Cedex 5

• Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associat … Ended recruitment
  2024-515433-15-02 6 2025-01-29 acute coronary syndrome
• CLINICAL STUDY TO TEST STEM CELLS FOR THE TREATMENT OF LONG-TERM, NON-HEALING VENOUS LEG ULCERS Ended recruitment
  2024-512720-11-00 5 2025-01-16 chronic venous ulcers (CVU)
• ANRS0407s -LKV.Cov40. A phase 1/2 multicenter, randomized study of the safety and immunogenicity of a sub-unit protein CD40.RBDv bivalent CO … Ended recruitment
  2023-504594-20-00 1 2025-01-06 Healthy volunteers
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL C … Ended recruitment
  2024-514032-25-00 4 2024-12-11 Patients with a histilogically confirmed diagnosis of cervical squamou
• A study looking at how effective and safe AZD7798 is in people with Crohn's disease Ended recruitment
  2023-510487-12-00 4 2024-11-29 Crohn's Disease
• Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph … Ended recruitment
  2023-505989-29-00 5 2024-11-21 Extensive stage small cell lung cancer (ES-SCLC)
• DAPAgliflozine to attenuate cardiac RemOdeling afTEr aCuTe myOcardial infarction Ended recruitment
  2024-511882-13-01 5 2024-11-19 Cardiac failure
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti- … Ended recruitment
  2024-513540-29-00 5 2024-11-07 Breast Cancer
• ALS phase II study of NX210c (SEALS) Ended recruitment
  2023-508895-13-00 4 2024-10-25 Amyotrophic Lateral Sclerosis (ALS)
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• Phase I trial of the new drug PhOx430 (inhibitor of the enzyme glucosaminyltransferase V) in patients with advanced solid tumors; first test … Ended recruitment
  2024-516574-30-00 1 2024-10-15 Adult patients with advanced or metastatic solid malignancies with rad
• JAK1 inhibitor treatment of inflammatory liver adenomas Ended recruitment
  2023-505278-13-00 4 2024-10-01 -women with an inflammatory HCA proven at histology and with at least
• A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, … Ended recruitment
  2023-505739-12-01 5 2024-09-30 Chronic Inducible Urticaria (CINDU)
• Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder Ended recruitment
  2023-505892-56-00 5 2024-09-30 Major Depressive Disorder
• ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended recruitment
  2023-509716-29-00 9 2024-09-23 Solid Tumors, Colorectal Cancer and Breast Cancer
• An open-label randomized trial of zanidatamab for advanced HER2positive biliary tract cancer Ended recruitment
  2023-508219-21-00 5 2024-09-12 BTC - Biliary Tract Cancer
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit … Ended recruitment
  2023-506335-15-00 5 2024-07-18 Major Depressive Disorder
• Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell … Ended recruitment
  2023-503594-38-00 1 2024-07-15 Select B-Cell malignancies.
• AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT … Ended recruitment
  2023-508130-33-00 9 2024-07-03 ADVANCED OR METASTATIC BREAST CANCER
• Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone … Ended recruitment
  2023-508310-41-00 4 2024-06-26 Multiple myeloma
• Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended recruitment
  2023-508235-31-00 5 2024-06-17 Atopic Dermatitis

Showing 481–504 of 830 trials